Article Text

Download PDFPDF

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy
  1. Shu Su1,
  2. Baorui Liu1 and
  3. Zhengyun Zou2
  1. Aff1 grid.41156.37000000012314964XThe Comprehensive Cancer Centre of Drum Tower HospitalMedical School of Nanjing University Nanjing China
  2. Aff2 grid.41156.37000000012314964XThe Comprehensive Cancer Center of Drum-Tower HospitalMedical School of Nanjing University & Clinical Cancer Institute of Nanjing University Nanjing China

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Strategies that enhance the function of T cells are critical for immunotherapy.


Here we described for the first time a non-viral mediated approach to reprogram primary human T cells by disruption of PD-1.


We showed that the gene knockout of PD-1 by electroporation of plasmids encoding sgRNA and Cas9 was technically feasible. The disruption of PD-1 resulted in significant reduction of PD-1 expression but didn't affect the viability of primary human T cells. Cellular immune response of the gene modified T cells was characterized by up-regulated IFN-γ production and enhanced cytotoxicity.


These results suggest that we have established an approach for efficient checkpoint inhibitor disruption, providing a new strategy for targeting checkpoint inhibitors to improve the efficacy of T cell based adoptive therapies.



The authors thank the entire Huang Lab and Liu Lab for their support and advice. This work was funded by grants from the National Natural Science Foundation of China (Grant No. 81172281, 81000980, 81220108023, 81172094).


  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.